Lunit Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Beomseok Brandon Suh

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	geen gegevens

Recente managementupdates

Recent updates

Here's Why We're Not At All Concerned With Lunit's (KOSDAQ:328130) Cash Burn Situation

Apr 19

CEO

Beomseok Brandon Suh

no data

Tenure

Mr. Beomseok Brandon Suh is Chief Executive Officer of Lunit Inc. He studied medicine in Seoul National University College of Medicine and is a board certified physician in Family Medicine, trained at Seou...

Lunit Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Lunit Announces the Appointment of Teri Thomas as Chief Business Officer of Its Cancer Screening Group

Lunit Announces the Appointment of Teri Thomas as Chief Business Officer of Its Cancer Screening Group

Recent updates

Price target decreased by 42% to ₩58,000

Lunit's Ai for Tuberculosis Detection Tops in 12-Product Comparative Study

Lunit Announces the Appointment of Teri Thomas as Chief Business Officer of Its Cancer Screening Group

Lunit Announces the Appointment of Teri Thomas as Chief Business Officer of Its Cancer Screening Group

Lunit to Showcase 7 Studies at Asco 2024, Including Ai Innovations in Her2 Quantification, and Multimodal Predictive Models for Immunotherapy Response

Lunit Inc. announced that it expects to receive KRW 171.5 billion in funding from a group of investors

Here's Why We're Not At All Concerned With Lunit's (KOSDAQ:328130) Cash Burn Situation

Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals

Lunit Announces Publication of New Study Featuring Lunit SCOPE IO

Lunit Inc. (KOSDAQ:A328130) agreed to acquire Volpara Health Technologies Limited (ASX:VHT) from Harbour Asset Management Limited and others for AUD300 million.

New minor risk - Shareholder dilution

Lunit Unveils Prognostic Insights for Colon Cancer - Published in Npj Precision Oncology

Lunit Unveils Prognostic Insights for Colon Cancer - Published in Npj Precision Oncology

Lunit Announces to Unveil Eight Groundbreaking Abstracts At the Radiological Society of North America

Third quarter 2023 earnings released: ₩948 loss per share (vs ₩1,576 loss in 3Q 2022)

Lunit Inc. Receives U.S. Food and Drug Administration (FDA) 510(K) Clearance for its 3D Breast Tomosynthesis (DBT) Ai Solution, Lunit Insight DBT

Lunit Inc. has completed a Follow-on Equity Offering in the amount of KRW 200.20077 billion.

Lunit Inc. Announces Collaborative Study with the Samsung Medical Center Assessed Tumor-Infiltrating Lymphocytes

New Study Demonstrates Lunit Inc. Scope Io's Effectiveness to Predict Biliary Tract Cancer Therapy Outcomes - Findings to Be Presented At the ESMO 2023

Lunit Presents Study on Predicting Treatment Response by HER2 Analysis in Colorectal Cancer

Lunit Inc. Provides Revenue Guidance for the Second Half of the Year 2022

CEO

Tenure